SITCSection 5
U.S. imports of glands, organ extracts & heparin for organo-therapeutic use (SITC 54162) totaled $18.5M in April 2026, traded with 41 countries.
Importers of Glands, Organ Extracts & Heparin for Organo-Therapeutic Use paid $30K in duties in April 2026 — an effective duty rate of 10% on $302K in dutiable value, based on actual customs collections rather than the published tariff schedule. Glands, Organ Extracts & Heparin for Organo-Therapeutic Use imports of $18.5M in April 2026 ran 20% below the year-to-date monthly average of $23.0M.
Last updated: April 2026 dataDried glands, organ extracts, and other human or animal-derived materials prepared for organo-therapeutic use — most notably heparin and its salts — represent a biologically sensitive import category with significant supply-chain scrutiny following past adulteration incidents in the heparin supply chain. FDA regulates heparin as a drug and requires that foreign manufacturers of heparin API be registered and inspected; the agency has maintained heightened vigilance over porcine intestine-derived heparin sourcing. Importers should verify that each lot is accompanied by full traceability documentation back to the animal source, as FDA may detain shipments from facilities with unresolved inspection findings.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
A major adulteration incident involving contaminated heparin API led FDA to significantly strengthen oversight of this supply chain. The agency now requires foreign heparin API manufacturers to be registered and subject to inspection, and it monitors sourcing of porcine intestinal mucosa — the primary raw material — for traceability and quality control failures.
Potentially, yes. Certain animal-derived biological materials may trigger USDA APHIS review for disease risk, particularly if derived from species or countries subject to animal disease restrictions. Importers should consult both FDA and APHIS import requirements before shipping, as dual-agency review can affect entry timelines.
Supplier Network
Get discovered by U.S. importers searching for HS 54162 — Glands, Organ Extracts & Heparin for Organo-Therapeutic Use. Be the first supplier listed.
| Country | Imports | Exports | Balance |
|---|---|---|---|
| CHINA | $8.4M | $1.7M | -$6.7M |
| SWEDEN | -- | $7.7M | +$7.7M |
| KOREA, SOUTH | $67K | $6.3M | +$6.2M |
| INDIA | $4.3M | $950K | -$3.4M |
| CANADA | $409K | $4.7M | +$4.3M |
Monthly import values over time